两融数据显示，该股最新融资余额为2.63亿元，近5日增加3148.95万元，增幅为13.60%。（数据宝） 8月8日天智航大宗交易一览 | 成交量 | 成交金额 （万元） | 成交价格 | 相对当日收盘折 溢价（%） | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | | （元） | | | | | 15.00 | 255.30 | 17.02 | -9.99 | 中信证券股份有限公司总 | 国投证券股份有限公 | | | | | | 部(非营业场所) | 司江苏分公司 | | 15.00 | 255.30 | 17.02 | -9.99 | 中信证券股份有限公司总 | 国投证券股份有限公 | | | | | | 部(非营业场所) | 司江苏分公司 | （文章来源：证券时报网） 天智航8月8日大宗交易平台共发生2笔成交，合计成交量30.00万股，成交金额510.60万元。成交价格均 为17.02元，相对今日收盘价折价9.99%。 进一步统计，近3个月内该股累计发生4笔大宗交易，合计成交金额为940.80万元。 证券时报·数据宝统计显 ...

8月8日，天智航大宗交易成交30万股，成交额510.6万元，占当日总成交额的1.71%，成交价17.02元，较市场收盘价18.91元折价9.99%。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) | 成交金额(万元) | 成交量( *) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-08 | 天智航 | 688277 | 17.02 | 255.3 15 | | 中信证券股份有限 公司总部(非营业 | 国投证券股份有限 公司江苏分公司 | | | | | | | | | 场所) | | | | | | | | | | 中信证券股份有限 | 国投证券股份有限 | | | 2025-08-08 | 天智航 | 688277 | 17.02 | 255.3 ાર | | 公司总部(非营业 | 公司江苏分公司 | | | | | | | | | 场所) | | | ...

Core Insights - As of August 7, a total of 143 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stock with the longest consecutive net inflow is Huicheng Environmental, which has seen net buying for 19 trading days [1] Summary by Related Categories Stocks with Significant Net Inflows - Huicheng Environmental has the highest consecutive net inflow days at 19 [1] - Other notable stocks with substantial net inflow days include: - China Baowu Steel with 13 days [1] - Jichuan Pharmaceutical with 12 days [1] - Tianzhihang, Zhejiang Communications, and China High-Tech each with 11 days [1] - Haizheng Pharmaceutical, Caixun Technology, Taijing Technology, Sailun Biotech, and Tanjia with 10 days each [1]

Core Insights - As of August 6, a total of 117 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stocks with the longest streak of net financing inflows are Chengdi Xiangjiang and Huicheng Environmental Protection, both achieving 18 consecutive trading days of net inflows [1] - Other notable stocks with significant net financing inflows include Juhe Materials (15 days), China Baoan (12 days), Jiuri New Materials, New Mileage, Jichuan Pharmaceutical, Cangge Mining, Tianzhihang, and Zhejiang Jiaoke, each with 10 to 11 consecutive trading days of net inflows [1]

Group 1 - The National Healthcare Security Administration (NHSA) has announced the optimization of drug procurement measures, including the inclusion of 55 drugs in the upcoming procurement round [4] - The AI healthcare sector is expected to accelerate commercialization due to supportive policies, particularly in areas like AI pathology diagnosis, AI imaging, and AI pharmaceuticals [4][5] - The market for surgical robots in China is projected to exceed 70 billion yuan by 2030, driven by aging population and uneven distribution of medical resources [5] Group 2 - The "Artificial Intelligence +" policy marks a new phase of large-scale, commercial, and ecological development in AI healthcare [6] - AI healthcare applications are expanding into areas such as cancer screening, critical illness management, and chronic disease management, addressing key pain points in the healthcare system [6][7] - Companies are encouraged to focus on various AI healthcare applications, including AI in pharmaceuticals, medical imaging, and genetic sequencing [6][7]

Core Insights - As of August 5, a total of 116 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stocks with the longest consecutive net inflow days are Huicheng Environmental Protection and Chengdi Xiangjiang, both achieving 17 consecutive trading days of net inflows [1] - Other notable stocks with significant consecutive net inflow days include Gaomei Co., Juhe Materials, China Baoan, Langkun Technology, Jichuan Pharmaceutical, Jiuri New Materials, Xinlicheng, Cangge Mining, Tianzhihang, and Jingcheng Co., with inflow days ranging from 9 to 15 [1]

证券之星消息，8月4日，天智航（688277）融资买入2414.5万元，融资偿还2414.17万元，融资净买入 0.34万元，融资余额2.37亿元，近3个交易日已连续净买入累计500.66万元，近20个交易日中有14个交易 日出现融资净买入。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-04 | 3365.00 | 2.37亿 | 2.87% | | 2025-08-01 | 499.50万 | 2.37亿 | 2.99% | | 2025-07-31 | 8300.00 | 2.32亿 | 2.89% | | 2025-07-30 | 422.85万 | 2.32亿 | 2.92% | | 2025-07-29 | 1230.55万 | 2.27亿 | 2.80% | 融券方面，当日融券卖出1000.0股，融券偿还0.0股，融券净卖出1000.0股，融券余量1700.0股。 | 交易日 | 融券净卖用(股) | | 融券余重(股) | 融券余额(元) | | --- | --- | --- | --- | ...

天眼查商业履历信息显示，北京天智航医疗科技股份有限公司，成立于2010年，位于北京市，是一家以 从事专用设备制造业为主的企业。企业注册资本44939.1939万人民币，实缴资本13181万人民币。公司 法定代表人为张送根。 通过天眼查大数据分析，北京天智航医疗科技股份有限公司共对外投资了16家企业，参与招投标项目 245次，知识产权方面有商标信息55条，专利信息517条，此外企业还拥有行政许可31个。 来源：金融界 金融界消息 截至2025年8月1日收盘，天智航U（688277）报收于17.5元，下跌1.24%，换手率2.44%，成 交量11.06万手，成交金额1.95亿元。 资金流向方面，今日主力资金净流出1617.75万元，占比成交额8.29%。其中，超大单净流出476.49万 元、占成交额2.44%，大单净流出1141.26万元、占成交额5.85%，中单净流出流入650.24万元、占成交 额3.33%，小单净流入967.52万元、占成交额4.96%。 天智航最新一期业绩显示，截至2025一季报，公司营业总收入5858.38万元、同比增长102.40%，归属净 利润1320.49万元，同比减少31.22% ...

金融界消息 截至2025年7月31日收盘，天智航U（688277）报收于17.72元，上涨1.08%，换手率4.52%， 成交量20.45万手，成交金额3.70亿元。 资金流向方面，今日主力资金净流入3040.86万元，占比成交额8.22%。其中，超大单净流入747.75万 元、占成交额2.02%，大单净流入2293.11万元、占成交额6.2%，中单净流出流入710.36万元、占成交额 1.92%，小单净流出3751.23万元、占成交额10.14%。 天智航最新一期业绩显示，截至2025一季报，公司营业总收入5858.38万元、同比增长102.40%，归属净 利润1320.49万元，同比减少31.22%，扣非净利润3124.68万元，同比增长21.17%，流动比率3.330、速动 比率3.092、资产负债率23.85%。 天眼查商业履历信息显示，北京天智航医疗科技股份有限公司，成立于2010年，位于北京市，是一家以 从事专用设备制造业为主的企业。企业注册资本44939.1939万人民币，实缴资本13181万人民币。公司 法定代表人为张送根。 通过天眼查大数据分析，北京天智航医疗科技股份有限公司共对外投资了16 ...

Summary of Tianzhihang Conference Call Company Overview - **Company**: Tianzhihang - **Industry**: Orthopedic Surgical Robotics Key Points and Arguments Industry and Market Dynamics - In the first half of 2025, the number of tenders for orthopedic surgical robots increased by over 50% year-on-year, with surgical volume growth exceeding 30%, reaching 11,000 cases, indicating a strong market recovery [2][3] - The company aims to accelerate entry into developed markets such as Europe, the US, and Japan, with plans to achieve a breakthrough in Europe and initiate FDA certification, expected by around 2027 [2][6] Product Development and Innovations - Tianzhihang's new generation "Tianji 4 Rui" robot has been approved, featuring a 7-axis medical robotic arm specifically for orthopedic surgeries, with capabilities for automatic registration and surgical planning [2][4] - The company has also received approval for a mobile CT imaging product, enhancing its product portfolio and technological strength [2][4] Business Model and Growth Strategy - The company is promoting a hospital purchasing service model, which has doubled in growth over the past two years, currently focused on Beijing, with plans to expand to the Yangtze River Delta and Pearl River Delta regions [2][7] - The national medical insurance bureau is formulating pricing guidelines for surgical robots, expected to be implemented this year, which will provide substantial support for Tianzhihang's business development [2][8] Financial Performance and Projections - In Q1 2025, the company's revenue doubled year-on-year, with surgical robot revenue increasing by over 400%. The surgical volume rose from 8,000 cases in Q1 2024 to 11,000 cases in Q1 2025 [3][24] - The company targets a revenue growth of no less than 20% for the year, with expected losses reduced to between 50 million and 70 million [5][24] Competitive Landscape and Policy Impacts - The tender market is expected to see a shift away from price-based competition towards a focus on technology and product quality, which will benefit high-quality companies like Tianzhihang [5][13] - The company's market share rebounded to 50% in Q1 2025, up from approximately 30%-40% in 2024, indicating a recovery in competitive positioning [5][14] Challenges and Responses - The orthopedic surgical robot sector has faced severe internal competition, leading to price wars. Tianzhihang has responded with a multi-product strategy, including low-end models for grassroots hospitals and high-end multifunctional machines [12] - The company is addressing the challenges posed by price pressures and regulatory scrutiny, which have affected high-priced products' bidding success [12][13] Future Outlook - The company anticipates a continued upward trend in market share and revenue growth, with expectations of achieving a 40%-50% growth rate for the year [24][25] - The introduction of new pricing policies is expected to alleviate some of the financial constraints currently faced by the surgical robot industry [10][16] Additional Important Insights - The average annual surgical volume for mature surgical robots is around 200 to 300 cases, with a potential ceiling of 350 cases [18] - The new generation of robots incorporates advanced features such as a 400 Hz optical tracking camera for improved precision and efficiency in surgeries [20][22] - The company has established a subsidiary and secured 90 million yuan in funding to support the development of imaging products [4]